Since April 15 and 17, 2009, when the first two cases of novel influenza A (H1N1) infection were identified from two southern California counties, novel influenza A (H1N1) cases have been documented throughout the world, with most cases occurring in the United States and Mexico.

In the United States, early reports of illnesses associated with novel influenza A (H1N1) infection indicated the disease might be similar in severity to seasonal influenza, with the majority of patients not requiring hospitalization and only rare deaths reported, generally in persons with underlying medical conditions.

LONDON, May 19 /PRNewswire/ --

- Study Results Demonstrate Patients Adhere to Treatment Regimens With EVISTA(R)

To view a Vodcast of Professor Peyman Hadji presenting the data click the following link: http://62.193.238.61/blueprinttv/expert/Expert-Opinion.html

To view a Vodcast of a Patient's Perspective click the following link: http://62.193.238.61/blueprinttv/expert/The-Patient-Perspetive.html

LONDON, May 19 /PRNewswire/ --

Data presented today at the 8th European Congress on Menopause (EMAS) demonstrated that the majority of osteoporosis patients treated with EVISTA(R) (raloxifene) stay on therapy for the first two years.

LONDON, May 19 /PRNewswire/ --

- Study Results Demonstrate Patients Continue to Adhere to Treatment With Raloxifene

To view a Vodcast of Professor Peyman Hadji presenting the data click here: http://62.193.238.61/blueprinttv/expert/Expert-Opinion.html

To view a Vodcast of a Patient's Perspective click here:

http://62.193.238.61/blueprinttv/expert/The-Patient-Perspetive.html

WARRENDALE, Pennsylvania, May 18 /PRNewswire/ --

MEDRAD Interventional(TM)/Possis(R) today announced that it has reached key milestones in bringing the Paccocath(R) Technology closer to market as an option for the over 14 million patients in the United States and Europe who suffer from Peripheral Arterial Disease (PAD). These milestones include the selection of physician investigators for U.S. clinical trials and the completion of a new state-of-the-art manufacturing facility.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )

CAMBRIDGE, Massachusetts, May 18 /PRNewswire/ --

A potential new player in Cameroon's mobile market and regulatory pressure to cut prices will help to more than double the country's mobile penetration by 2014, according to a new report from Pyramid Research (www.pyr.com), the telecom research arm of the Light Reading Communications Network (www.lightreading.com).

BARCELONA, Spain, May 18 /PRNewswire/ --

CeloNova BioSciences, Inc., today announced that it will showcase the technology behind the CATANIA(TM) Coronary Stent System featuring a NanoThin Polyzene(R)-F surface treatment as part of the Company's participation in the EuroPCR conference May 19-22.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090518/CL18788) (Photo: http://www.newscom.com/cgi-bin/prnh/20081007/CLTU035-b)

GENEVA, Switzerland, May 18 /PRNewswire/ --

- Global Epidemic Kills One Person Every 30 Seconds and One Million People Will Die Before the World Health Assembly Meets Again in 2010

Ahead of the second annual World Hepatitis Day, the World Hepatitis Alliance today called on governments not to forget the plight of 500 million people living with hepatitis B and C, as the World Health Assembly postpones discussion of a World Health Organization (WHO) resolution on viral hepatitis - one of the biggest threats to global health.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090518/347266 )

TEL AVIV, Israel, May 18 /PRNewswire/ --

- Studio - The innovative addition to the TestShell suite offers advanced drag-and-drop multi-sequence test creation for complex testing environments

QualiSystems, a leading provider of advanced test automation solutions, announced today the launch of TestShell Studio, the innovative latest addition to the TestShell system, at Interop Las Vegas, May 19th - 21st, booth #1956.

SUNNYVALE, California, May 18 /PRNewswire/ --

- Frost Sullivan Research Declares Spirent as the Market Leader in Enterprise Network Test Measurement Solutions for Research and Evaluation Labs

Spirent Communications plc (http://www.spirent.com/ ) (LSE: SPT), a leader in network, service and device testing, has been recognized by Frost Sullivan (http://www.frost.com/ ) as the leader in enterprise network test and measurement solutions for research and evaluation labs. According to Frost Sullivan's recent report that surveyed the enterprise network system testing and monitoring solutions market, Spirent maintained its leadership position with more the one-third of the market share in the research and evaluation lab segment.

GENEVA, Switzerland, May 18 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, confirms its commitment to investing in the therapeutic area of fertility, after Merck KGaA informed earlier today the Oslo Stock Exchange of its withdrawal of the voluntary cash tender offer for MediCult A/S, a leader in Assisted Reproductive Technologies (ART), as the required share threshold was not reached in the set timeframe.

Merck Serono has a proud heritage of leadership in the field of fertility and will actively pursue opportunities that will contribute to bring further innovation to physicians and patients, and increase the success rate of fertility treatments, said Dr. Richard Douge, Executive Vice President Global Marketing at Merck Serono.